author-photo

Kate Fife

Cambridge University Hospitals NHS Foundation Trust
University of Cambridge

72

Papers

2801

Citations

Citation Trend

Filter By

Papers (47) Sort By

Journal Conference Others

Data for: Combined radiotherapy and new systemic therapies - have we moved beyond palliation?

2021
- Kate Fife
Show All
- Source
- Cite
- Save
Citations (0)
Dynamic biomarker and imaging changes from a phase II study of pre- and post-surgical sunitinib.

2021 BJUI
Show All
- Source
- Cite
- Save
Citations (1)
The WIRE study a phase II, multi-arm, multi-centre, non-randomised window-of-opportunity clinical trial platform using a Bayesian adaptive design for proof-of-mechanism of novel treatment strategies in operable renal cell cancer - a study protocol.

2021 BMC Cancer
Show All
- Source
- Cite
- Save
Citations (0)
What is the role of real-world data in metastatic renal cell cancer?

2021 Future Oncology
- Will Ince
- Kate Fife
Show All
- Source
- Cite
- Save
Citations (0)
Selection of oncogenic mutant clones in normal human skin varies with body site.

2020 Cancer Discovery
Show All
- Source
- Cite
- Save
Citations (17)
Individualised Predictions of the Survival Benefit Due to Adjuvant Therapy in a Randomised Trial of Sorafenib After Nephrectomy for Localised Renal Cell Carcinoma

2020
Show All
- Source
- Cite
- Save
Citations (0)
Treatment patterns and health outcomes in metastatic renal cell carcinoma patients treated with targeted systemic therapies in the UK.

2020 BMC Cancer
Show All
- Source
- Cite
- Save
Citations (3)
Treatment patterns and health outcomes in metastatic renal cell carcinoma patients treated with targeted systemic therapies in the UK

2020
Show All
- Source
- Cite
- Save
Citations (0)
741P Clinical outcomes stratified by Charlson Comorbidity Index (CCI) score from a retrospective study of patients with advanced renal cell carcinoma (aRCC) who received cabozantinib as part of the UK Managed Access Program (MAP)

2020 Annals of Oncology
Show All
- Source
- Cite
- Save
Citations (0)
CERES, a retrospective study of patients with advanced renal cell carcinoma who received cabozantinib as part of the UK Managed Access Program: Baseline characteristics and clinical outcomes

2020
Show All
- Source
- Cite
- Save
Citations (0)